Adeno-associated virus (AAV) capsid engineering is an emerging approach to advance
gene therapy. However, a systematic analysis on how each capsid amino acid contributes to …

Glycosaminoglycans (GAGs) are complex carbohydrates that are ubiquitously present on
the cell surface and in the extracellular matrix. Interactions between GAGs and pathogens …

Adeno-associated viruses (AAVs) are being developed as gene therapy vectors, and their
efficacy could be improved by a detailed understanding of their viral capsid structures. AAV …

We report a DNA shuffling–based approach for developing cell type–specific vectors
through directed evolution. Capsid genomes of adeno-associated virus (AAV) serotypes 1–9 …

Post‐translational modifications in viral capsids are known to fine‐tune and regulate several
aspects of the infective life cycle of several viruses in the host. Recombinant viruses that are …

Gene transfer vectors derived from the adeno-associated virus (AAV) have recently received
increasing attention due to substantial therapeutic benefit in several clinical trials …

Adeno-associated virus (AAV) has attracted considerable interest as a gene therapy vector
over the past decade. In all, 85% of the current 2052 PubMed references on AAV (as of …

While protein therapeutics are one of the most successful class of drug molecules, they are
expensive and not suited for treating chronic disorders that require long-term dosing. Adeno …

In the past 10 years, there has been tremendous progress made in the field of gene therapy.
Effective treatments of Leber congenital amaurosis, hemophilia, and spinal muscular …

Abstract Adeno‐associated virus (AAV), a single‐stranded DNA parvovirus, is emerging as
one of the leading gene therapy vectors owing to its nonpathogenicity and low …